Nirogacestat

Drug Overview

Nirogacestat is an oral, selective, small molecule inhibitor of the gamma-secretase enzyme complex. This Targeted Therapy disrupts the Notch signaling pathway, which is implicated in the growth of various tumors, most notably desmoid tumors (also known as aggressive fibromatosis). It represents the first FDA-approved treatment specifically for this rare, locally invasive, non-cancerous tumor type.

• Generic Name: Nirogacestat
• US Brand Names: Ogsiveo®
• Drug Class: Gamma-Secretase Inhibitor (GSI), Targeted Therapy
• Route of Administration: Oral Tablet
• FDA Approval Status: Approved for a non-oncological indication (Desmoid Tumors).

Mechanism of Action

Molecular Mechanism (Notch Pathway Inhibition)

• Target: Nirogacestat selectively targets and inhibits the gamma-secretase enzyme complex.
• Gamma-Secretase Function: This enzyme is a transmembrane aspartyl protease responsible for cleaving several proteins. Its most critical substrate is the Notch receptor protein.
• Notch Activation: Normally, when the Notch receptor is activated by a ligand, the gamma-secretase enzyme cleaves the receptor’s transmembrane domain, releasing the Notch Intracellular Domain (NICD).
• Gene Transcription: The NICD then translocates into the cell nucleus, where it binds to and activates transcription factors. This results in the expression of genes that promote cell proliferation, survival, and differentiation, all of which drive the growth of desmoid tumors.
• Nirogacestat Action: By inhibiting gamma-secretase, nirogacestat prevents the cleavage of the Notch receptor. This blocks the release and nuclear translocation of NICD, effectively shutting down the aberrant Notch signaling cascade and suppressing the growth of desmoid tumor cells.

FDA Approved Clinical Indications

Nirogacestat is FDA-approved for the following indication:

• Non-oncological uses:
  • Treatment of adult patients with progressing desmoid tumors (aggressive fibromatosis) who require systemic treatment.
• Oncological uses:
  • Currently, nirogacestat has no FDA-approved oncological uses.

Dosage and Administration Protocols

Administer orally, with or without food. Swallow whole; do not crush or split. Monitor for gastrointestinal side effects and adjust as needed.

Clinical Efficacy and Research Results

The FDA approval of nirogacestat in November 2023 was primarily based on the results of the pivotal, international, Phase III DeFi trial (NCT03785964), which demonstrated significant efficacy and improved patient outcomes in adults with progressing desmoid tumors.

• Progression-Free Survival (PFS): Nirogacestat significantly improved PFS compared to placebo. The median PFS was not reached in the nirogacestat arm, compared to 15.1 months in the placebo arm. This translated to a 71% reduction in the risk of disease progression or death (Hazard Ratio [HR] 0.29; p-value < 0.001).
• Objective Response Rate (ORR): Nirogacestat achieved a statistically and clinically meaningful ORR (tumor shrinkage of 30% or more) of 41%, compared to only 8% in the placebo group (p-value < 0.001).
• Long-Term Efficacy (2024-2025 Data): Long-term data from the DeFi trial confirmed sustained benefit, with the ORR improving to 45.7% in patients who received nirogacestat for up to four years, demonstrating further tumor size reduction and durable responses over time.
• Patient-Reported Outcomes (PROs): Patients receiving nirogacestat reported sustained and clinically meaningful improvements in key PRO measures, including significant reductions in pain, disease-specific symptom burden, and improved physical functioning.

Safety Profile and Side Effects

Black Box Warning

Nirogacestat does not carry a Black Box Warning. However, there are serious risks related to reproductive toxicity and hepatotoxicity that require careful management.

Common Side Effects (>10%)

• Gastrointestinal: Diarrhea (very common, >80% in trials), Nausea, Abdominal pain, Stomatitis (mouth sores).
• Dermatologic: Rash, Alopecia (hair loss), Dry skin.
• Metabolic/Constitutional: Fatigue, Hypophosphatemia (low phosphate, >40% incidence), Hypokalemia (low potassium), Elevated liver enzymes (ALT/AST).
• Reproductive Toxicity: Ovarian dysfunction (amenorrhea, hot flashes) in women of childbearing potential (observed in approximately 75% of women in the DeFi trial).

Serious Adverse Events

• Hepatotoxicity: Significant increases in ALT or AST that may require dose reduction or permanent discontinuation.
• Severe Diarrhea/Metabolic Derangements: Grade 3 or 4 diarrhea or severe hypophosphatemia/hypokalemia that may lead to dehydration and organ dysfunction if not managed aggressively.
• Non-Melanoma Skin Cancer: Possible risk of basal cell or squamous cell carcinoma.

Management Strategies

• Gastrointestinal: Diarrhea and nausea are managed with prompt use of anti-diarrheals (e.g., loperamide), antiemetics, and aggressive hydration. Dose reduction is required for persistent severe diarrhea.
• Metabolic: Hypophosphatemia and Hypokalemia require immediate oral supplementation.
• Ovarian Dysfunction: Counseling on fertility preservation prior to treatment is crucial for women of childbearing potential. Ovarian function often recovers after discontinuation, but monitoring is necessary.
• Hepatotoxicity: Liver function tests (ALT/AST) must be monitored regularly. Drug should be withheld or permanently discontinued based on the degree of elevation.

Connection to Stem Cell and Regenerative Medicine

Nirogacestat’s mechanism as a gamma-secretase inhibitor opens avenues for research beyond desmoid tumors, particularly in oncology and immunology.

• Oncology Combinations: The inhibition of gamma-secretase also preserves B-cell maturation antigen (BCMA) on the cell surface of multiple myeloma cells. This action is being actively investigated in combination trials to see if nirogacestat can enhance the effectiveness of BCMA-directed immunotherapies, such as CAR T-cell therapy and bispecific T-cell engagers (BiTEs), by increasing the target density and reducing soluble BCMA “decoys.”
• Pediatric and Neoadjuvant Studies: Research is ongoing to evaluate nirogacestat’s safety and efficacy in pediatric and adolescent patients with desmoid tumors and to assess its use in the neoadjuvant setting (before surgery) for patients with resectable disease.

Patient Management and Practical Recommendations

Pre-treatment Tests to Be Performed

• Liver Function Tests (LFTs): Baseline AST and ALT to establish hepatic function.
• Electrolytes: Baseline Serum Phosphate and Potassium.
• Pregnancy Test: Mandatory for women of childbearing potential before initiating treatment due to potential reproductive toxicity.
• Cardiology Assessment: Evaluation of QTc interval (ECG) is recommended, as cardiac rhythm abnormalities have been a class effect of some GSIs.

Precautions During Treatment

• Sun Protection: Use protective clothing and sunscreen due to the potential risk of non-melanoma skin cancer.
• Drug Interactions: Avoid grapefruit, starfruit, and Seville oranges, as these can affect nirogacestat metabolism (CYP3A4 inhibitor). Avoid certain gastric acid-reducing agents (antacids, H2 blockers, PPIs) within 2 hours of the nirogacestat dose.
• Reproductive Counseling: All women of reproductive potential must use effective non-hormonal contraception during treatment and for 1 week after the final dose.

Do’s and Don’ts

• DO: Take the tablets whole; do not crush, chew, or split them.
• DO: Take the dose at approximately the same time every morning and evening.
• DO: Immediately report severe diarrhea, persistent vomiting, or symptoms of liver problems (e.g., yellowing skin/eyes, dark urine).
• DON’T: Take a double dose if a dose is missed; skip the missed dose and take the next dose at the scheduled time.
• DON’T: Use grapefruit, starfruit, or Seville oranges during the entire treatment period.
• DON’T: Change contraception methods without consulting the oncology team.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.